| HOME >> BIOLOGY >> TECHNOLOGY |
SOUTH SAN FRANCISCO, Calif., April 15 /PRNewswire/ -- diaDexus, Inc. today announced the appointment of Fisher HealthCare as the exclusive customer channel for its new automated PLAC Test for the Hitachi, Hitachi Roche P-Modular and Olympus chemistry analyzers to U.S. hospital clinical laboratories. The new automated format was recently cleared by the U.S. Food & Drug Administration (FDA) enabling the test to run on these popular clinical chemistry analyzers.
The PLAC Test is the only blood test cleared by the FDA to assess risk for both coronary heart disease and ischemic stroke associated with atherosclerosis. Earlier detection and more aggressive treatment can prevent heart attacks and strokes. The PLAC Test measures lipoprotein-associated phospholipase A(2) (Lp-PLA(2)), a vascular-specific inflammatory enzyme implicated in the formation of rupture-prone plaque. It is plaque rupture and thrombosis, not stenosis, that cause the majority of cardiac events.
According to Patrick Plewman, president and chief executive officer of diaDexus, the agreement is an important milestone for the company as it expands the availability of the PLAC Test. "The PLAC Test provides new information, over and above traditional cardiovascular risk factors, to help identify individuals at increased risk of suffering a heart attack or stroke. This new relationship with Fisher HealthCare and its powerful sales force will help expand the number of clinical laboratories offering the PLAC Test," Plewman said.
Joe Bernardo, president of Fisher HealthCare, said "Fisher HealthCare is committed to providing comprehensive, high-value diagnostic tests in order to meet the needs of the labs, physicians, and patients we serve. This new automated version of the PLAC Test will help reduce the cost of running the test and improve turnaround time."
About diaDexus
diaDexus, Inc., a privately held diagnostics company based in South San
Francisco, is focused on the d
'/>"/>
| SOURCE diaDexus, Inc. Copyright©2008 PR Newswire. All rights reserved |